Recap: Hologic Q1 Earnings

Loading...
Loading...

Shares of Hologic HOLX increased in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share increased 368.85% year over year to $2.86, which beat the estimate of $2.17.

Revenue of $1,610,000,000 up by 89.30% from the same period last year, which beat the estimate of $1,400,000,000.

Guidance

Q2 EPS expected between $2.56 and $2.68.

Q2 revenue expected to be between $1,500,000,000 and $1,560,000,000.

How To Listen To The Conference Call

Date: Jan 27, 2021

Time: 04:30 PM

ET Webcast URL: https://events.globalmeet.com/Public/ClickToJoin/ZW5jPTJHZWIwU3FaRks2Qy9wWWRudFUxUnRzaHl1NW5jVGVodEtGUTJ0WFZJNjRkYTdUUmo3S3c0Zz09

Price Action

52-week high: $81.80

52-week low: $26.49

Price action over last quarter: down 4.12%

Company Description

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: breast health (44% of sales), diagnostics (39%) surgical (14%), and skeletal health (3%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (74%), followed by Europe (12%), Asia (9%), and other international markets (5%). Hologic is headquartered in Bedford, Massachusetts.

Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...